COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Frequently asked questions
What sector does COMPASS PATHW SP.ADR (5Y6) operate in?
COMPASS PATHW SP.ADR belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is COMPASS PATHW SP.ADR (5Y6) current stock price?
As of the latest data, COMPASS PATHW SP.ADR stock price is €9.95, with a previous close of €9.80. COMPASS PATHW SP.ADR gained €0.15 in the last trading session, representing a 1.53% increase.
What is COMPASS PATHW SP.ADR (5Y6) current market capitalization?
COMPASS PATHW SP.ADR market cap is approximately 1.38 billion.
What is COMPASS PATHW SP.ADR (5Y6) Earnings Per Share (EPS)?
The trailing EPS is -€3.22.
What is COMPASS PATHW SP.ADR (5Y6) EBITDA?
COMPASS PATHW SP.ADR EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -220.61 million.
Does COMPASS PATHW SP.ADR (5Y6) pay dividends?
No. COMPASS PATHW SP.ADR does not pay a dividend.
When is COMPASS PATHW SP.ADR (5Y6) next earnings report?
COMPASS PATHW SP.ADR is expected to release its next earnings report on September 30, 2026.
What is COMPASS PATHW SP.ADR (5Y6) beta (volatility) score?
COMPASS PATHW SP.ADR has a beta of 2.564, indicating very high volatility compared to the market.